Antibody-drug conjugates (ADCs) are cancer therapeutic agents comprised of an antibody,
a linker and a small-molecule payload. ADCs use the specificity of the antibody to target the …

The popularity of antibody drug conjugates (ADCs) has increased in recent years, mainly
due to their unrivalled efficacy and specificity over chemotherapy agents. The success of the …

Antibody-drug conjugates (ADCs) are one of fastest growing classes of oncology drugs in
modern drug development. By harnessing the powers of both cytotoxic chemotherapy and …

Abstract Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal
antibodies with precise targeting and payloads with efficient killing, show great clinical …

The marine environment is a rich source of biologically active molecules for the treatment of
human diseases, especially cancer. The adaptation to unique environmental conditions led …

The development of antibody-drug conjugates (ADCs) has significantly been advanced in
the past decade given the improvement of payloads, linkers and conjugation methods. In …

The emergence of antimicrobial resistance (AMR) is rapidly increasing and it is one of the
significant twenty-first century's healthcare challenges. Unfortunately, the development of …

Maytansine is a pharmacologically active 19-membered ansamacrolide derived from
various medicinal plants and microorganisms. Among the most studied pharmacological …

Monospecific antibodies have been utilised increasingly for anti-cancer drug targeting owing
to their ability to minimise off-target toxicity by binding specifically to a tumour epitope, hence …

While chemotherapy and radiotherapy remain the first-line approaches for the management
of most unresectable tumors, immunotherapy has emerged in the past two decades as a …